Cell-free DNA Fragmentomics and Second Malignant Neoplasm Risk in Patients with PTEN Hamartoma Tumor Syndrome
DOI10.5281/zenodo.11068432Zenodo11068432MaRDI QIDQ6694124
Dataset published at Zenodo repository.
3 Andrew Dhawan1 4, Charis Eng1 2, 4, 6, 7, 8, 5 Ying Ni2, Darren1 Liu 2, Lamis Yehia1
Publication date: 14 May 2024
Copyright license: Creative Commons Attribution 4.0 International
Supplementary dataset for manuscript Affiliations: 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA 3Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH 44195, USA 4Center for Personalized Genetic Healthcare, Medical Specialties Institute, Cleveland Clinic, Cleveland, OH 44195, USA 5Center for Immunotherapy and Precision Immuno-oncology, Cleveland Clinic, Cleveland, OH 44195, USA 6Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA 7Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA 8Germline High Risk Cancer Focus Group, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA Correspondence: Charis Eng, MD, PhD (https://orcid.org/0000-0002-3693-5145) Cleveland Clinic Genomic Medicine Institute 9500 Euclid Avenue NE50, Cleveland, OH 44195, USA Tel: +1 (216) 444-3440, Fax: +1 (216) 636-0009, E-mail: engc@ccf.org
This page was built for dataset: Cell-free DNA Fragmentomics and Second Malignant Neoplasm Risk in Patients with PTEN Hamartoma Tumor Syndrome
